Coluracetam MKC-231 Pharmaceutical Raw Nootropic Powder
Grundinformation
Coluracetam 135463-81-9
Produktname: Coluracetam MKC-231
Chemischer Name: N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-
1-yl)Acetamid
CAS-Nr.: 135463-81-9
Formel: C19H23N3O3
Reinheit:99%
Molekulargewicht:341.40
Aussehen:white crystal powder
Siedepunkt:634.1C at 760 mmHg C
Beschreibung:
Coluracetam (BCI-540) is a nootropic drug of the racetam family.Coluracetam (formerly known as MKC-231) was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer’s disease.
Coluracetam enhances high-affinity choline uptake (HACU) which is the rate-limiting step of acetylcholine (ACh) synthesis, and is the only known choline uptake enhancer to currently exist. Studies have shown
Coluracetam to improve learning impairment on a single oral dose given to rats which have been exposed to cholinergic neurotoxins. Subsequent studies have shown that it may induce long-lasting procognitive effects by changing the choline transporter regulation system.
Coluracetam MKC 231 Dosierung
Since the study subjects were rats, there aren’t any recommended human dosages, but there is a general guideline for conversion.
In rats, the dosage ranged between 1 mg/kg and 10 mg/kg per day. By using allometric scaling, the dose becomes 2.9 mg/kg in humans, so the average dose should not exceed 203.5 mg daily for someone in a typical weight class.
There isn’t very much information to indicate toxicity of Coluracetam, although doses given at the above increments showed no negative side effects. If you haven’t used a nootropic before, you may develop headache after use, which is a common in first time users. By stacking the Coluracetam with Choline, you’ll reduce this risk.
Verkaufsleiter